000 | 01964 a2200517 4500 | ||
---|---|---|---|
005 | 20250516054039.0 | ||
264 | 0 | _c20120315 | |
008 | 201203s 0 0 eng d | ||
022 | _a1538-8514 | ||
024 | 7 |
_a10.1158/1535-7163.MCT-11-0243 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aAngelo, Laura S | |
245 | 0 | 0 |
_aCombining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. _h[electronic resource] |
260 |
_bMolecular cancer therapeutics _cNov 2011 |
||
300 |
_a2094-103 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
650 | 0 | 4 |
_aApoptosis _xdrug effects |
650 | 0 | 4 |
_aBenzhydryl Compounds _xpharmacology |
650 | 0 | 4 | _aCell Line, Tumor |
650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
650 | 0 | 4 |
_aCurcumin _xpharmacology |
650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xgenetics |
650 | 0 | 4 | _aDrug Synergism |
650 | 0 | 4 |
_aGene Expression Regulation, Neoplastic _xdrug effects |
650 | 0 | 4 |
_aHSP72 Heat-Shock Proteins _xgenetics |
650 | 0 | 4 |
_aHeat-Shock Proteins _xantagonists & inhibitors |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aMyosin-Light-Chain Phosphatase _xmetabolism |
650 | 0 | 4 |
_aNeurofibromatosis 2 _xdrug therapy |
650 | 0 | 4 |
_aNeurofibromin 2 _xmetabolism |
650 | 0 | 4 | _aPhosphorylation |
650 | 0 | 4 | _aProtein Binding |
650 | 0 | 4 |
_aPyrrolidinones _xpharmacology |
650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
650 | 0 | 4 |
_aUp-Regulation _xdrug effects |
700 | 1 | _aWu, Ji Yuan | |
700 | 1 | _aMeng, Feng | |
700 | 1 | _aSun, Michael | |
700 | 1 | _aKopetz, Scott | |
700 | 1 | _aMcCutcheon, Ian E | |
700 | 1 | _aSlopis, John M | |
700 | 1 | _aKurzrock, Razelle | |
773 | 0 |
_tMolecular cancer therapeutics _gvol. 10 _gno. 11 _gp. 2094-103 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1158/1535-7163.MCT-11-0243 _zAvailable from publisher's website |
999 |
_c21143808 _d21143808 |